Medications included semaglutide (AOM and ADM, oral and injectable), liraglutide (AOM and ADM), exenatide (ADM), lixisenatide (ADM), tirzepatide (AOM and ADM), and dulaglutide (ADM)
Maximum benefit comes from integrating these peptides into comprehensive approaches that include dietary modifications, exercise, sleep optimization, stress management, and other interventions that support metabolic health and sustainable weight loss
Clinicians should adopt a balanced perspective , recognising that the overall health benefits of appropriate weight loss in type 2 diabetes typically outweigh theoretical concerns about bone density, whilst remaining vigilant about bone health in higher-risk individuals
Unfortunately, some semaglutide patients may never experience a reduction in symptoms